Most cited papers from BioNTech (Germany)

BioNTech (Germany)

What are the most cited papers from BioNTech (Germany)?

The most cited paper from BioNTech (Germany) is "Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer" (Uğur Şahin et al., 2017), with 2,536 citations. Next come "mRNA-based therapeutics — developing a new class of drugs" (2,505) and "COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses" (2,072).

Published TypeFieldAccessAuthorsCitations

Showing 50 of 61 papers. Every paper with more than 143 citations is listed.

Most cited papers, sortable by citations and release date
#	Paper
1	Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer Uğur Şahin et al. · Nature	4 Jul 2017	2,536
2	mRNA-based therapeutics — developing a new class of drugs Uğur Şahin, Katalin Karikó, Özlem Türeci · Nature Reviews Drug Discovery ReviewOpen access	19 Sep 2014	2,505
3	COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses Uğur Şahin et al. · Nature Open access	30 Sep 2020	2,072
4	Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy Lena M. Kranz et al. · Nature	Jun 2016	1,784
5	Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults Mark J. Mulligan et al. · Nature Open access	12 Aug 2020	1,598
6	Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer Luis Alfonso Rojas et al. · Nature Open access	10 May 2023	1,406
7	Mutant MHC class II epitopes drive therapeutic immune responses to cancer Sebastian Kreiter, Mathias Vormehr, Niels van de Roemer et al. · Nature Open access	22 Apr 2015	1,269
8	Personalized vaccines for cancer immunotherapy Uğur Şahin, Özlem Türeci · Science	22 Mar 2018	1,174
9	An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma Uğur Şahin et al. · Nature	29 Jul 2020	1,060
10	Actively personalized vaccination trial for newly diagnosed glioblastoma Norbert Hilf et al. · Nature	19 Dec 2018	954
11	Zika virus protection by a single low-dose nucleoside-modified mRNA vaccination Norbert Pardi et al. · Nature Open access	2 Feb 2017	903
12	BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans Uğur Şahin et al. · Nature Open access	27 May 2021	844
13	Exploiting the Mutanome for Tumor Vaccination John C. Castle, Sebastian Kreiter, Jan Diekmann et al. · Cancer Research Open access	12 Jan 2012	831
14	A Phase Ib Trial of Personalized Neoantigen Therapy Plus Anti-PD-1 in Patients with Advanced Melanoma, Non-small Cell Lung Cancer, or Bladder Cancer Patrick Alexander Ott et al. · Cell Open access	Oct 2020	775
15	Lipid nanoparticles enhance the efficacy of mRNA and protein subunit vaccines by inducing robust T follicular helper cell and humoral responses Mohamad‐Gabriel Alameh et al. · Immunity Open access	4 Nov 2021	772
16	BNT162b vaccines protect rhesus macaques from SARS-CoV-2 Annette B. Vogel et al. · Nature Open access	Feb 2021	761
17	Neutralizing Activity of BNT162b2-Elicited Serum Yang Liu, Jianying Liu, Hongjie Xia et al. · New England Journal of Medicine Open access	17 Feb 2021	633
18	Identification of neoantigens for individualized therapeutic cancer vaccines Franziska Lang, Barbara Schrörs, Martin Löwer et al. · Nature Reviews Drug Discovery ReviewOpen access	Feb 2022	591
19	A Facile Method for the Removal of dsRNA Contaminant from In Vitro-Transcribed mRNA Markus Baiersdörfer, Gábor Boros, Hiromi Muramatsu et al. · Molecular Therapy — Nucleic Acids Open access	26 Feb 2019	585
20	Key Parameters of Tumor Epitope Immunogenicity Revealed Through a Consortium Approach Improve Neoantigen Prediction Daniel K. Wells et al. · Cell Open access145 authors	Oct 2020	560
21	Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine–elicited human sera Alexander Muik, Ann-Kathrin Wallisch, Bianca Sänger et al. · Science Open access	29 Jan 2021	555
22	IL-1 and IL-1ra are key regulators of the inflammatory response to RNA vaccines Siri Tähtinen, Ann-Jay Tong, Patricia Himmels et al. · Nature Immunology	24 Mar 2022	539
23	Nucleoside-modified mRNA vaccines induce potent T follicular helper and germinal center B cell responses Norbert Pardi et al. · The Journal of Experimental Medicine Open access	8 May 2018	536
24	An RNA vaccine drives expansion and efficacy of claudin-CAR-T cells against solid tumors Katharina Reinhard et al. · Science	2 Jan 2020	525
25	A noninflammatory mRNA vaccine for treatment of experimental autoimmune encephalomyelitis Christina Krienke, LAURA D. KOLB, Elif Diken et al. · Science	7 Jan 2021	518
26	Self-Amplifying RNA Vaccines Give Equivalent Protection against Influenza to mRNA Vaccines but at Much Lower Doses Annette B. Vogel, Laura Ann Lambert, Ekaterina Kinnear et al. · Molecular Therapy Open access	5 Dec 2017	508
27	SARS-CoV-2 Neutralization with BNT162b2 Vaccine Dose 3 Ann Regina Falsey et al. · New England Journal of Medicine Open access	15 Sep 2021	420
28	Immunomic, genomic and transcriptomic characterization of CT26 colorectal carcinoma John C. Castle, Martin Löewer, Sebastian Boegel et al. · BMC Genomics Open access	2014	396
29	A Single Immunization with Nucleoside-Modified mRNA Vaccines Elicits Strong Cellular and Humoral Immune Responses against SARS-CoV-2 in Mice Dorottya I. Laczko et al. · Immunity Open access	30 Jul 2020	394
30	mRNA therapeutics in cancer immunotherapy Jan David Beck, Daniel Reidenbach, Nadja Salomon et al. · Molecular Cancer Open access	15 Apr 2021	391
31	Neutralization of SARS-CoV-2 Omicron by BNT162b2 mRNA vaccine–elicited human sera Alexander Muik, Bonny Gaby Lui, Ann-Kathrin Wallisch et al. · Science Open access	10 Feb 2022	390
32	BNT162b2-elicited neutralization of B.1.617 and other SARS-CoV-2 variants Jianying Liu, Yang Liu, Hongjie Xia et al. · Nature Open access	10 Jun 2021	381
33	FAST: a randomised phase II study of zolbetuximab (IMAB362) plus EOX versus EOX alone for first-line treatment of advanced CLDN18.2-positive gastric and gastro-oesophageal adenocarcinoma Uğur Şahin, Ö. Türeci, Georgy Moiseevich Manikhas et al. · Annals of Oncology Open access	21 Feb 2021	380
34	Improving mRNA-Based Therapeutic Gene Delivery by Expression-Augmenting 3′ UTRs Identified by Cellular Library Screening Alexandra G. Orlandini von Niessen, Marco A. Poleganov, Corina Rechner et al. · Molecular Therapy Open access	17 Dec 2018	374
35	D614G Spike Mutation Increases SARS CoV-2 Susceptibility to Neutralization Drew Weissman et al. · Cell Host & Microbe Open access	Dec 2020	354
36	Lyophilization provides long-term stability for a lipid nanoparticle-formulated, nucleoside-modified mRNA vaccine Hiromi Muramatsu, Kieu Lam, Csaba Bajusz et al. · Molecular Therapy Open access	4 Feb 2022	327
37	Intranodal Vaccination with Naked Antigen-Encoding RNA Elicits Potent Prophylactic and Therapeutic Antitumoral Immunity Sebastian Kreiter, Abderraouf Selmi, Mustafa Diken et al. · Cancer Research	7 Nov 2010	313
38	COVID-19 mRNA vaccines: Platforms and current developments Gabor Tamas Szabo, Azita J. Mahiny, Irena Vlatkovic · Molecular Therapy Open access	18 Feb 2022	310
39	RNA neoantigen vaccines prime long-lived CD8+ T cells in pancreatic cancer Zachary M. Sethna et al. · Nature Open access	19 Feb 2025	308
40	Nucleoside-modified mRNA immunization elicits influenza virus hemagglutinin stalk-specific antibodies Norbert Pardi, Kaela Parkhouse, Ericka Kirkpatrick et al. · Nature Communications Open access	16 Aug 2018	295
41	CLDN6-specific CAR-T cells plus amplifying RNA vaccine in relapsed or refractory solid tumors: the phase 1 BNT211-01 trial Andréas Mackensen et al. · Nature Medicine Open access	23 Oct 2023	290
42	Elimination of large tumors in mice by mRNA-encoded bispecific antibodies Christiane Stadler, Hayat Bähr-Mahmud, Leyla Çelik et al. · Nature Medicine	12 Jun 2017	289
43	Neutrophil extracellular trap-associated RNA and LL37 enable self-amplifying inflammation in psoriasis Franziska Herster, Zsofia Bittner, Nathan K. Archer et al. · Nature Communications Open access	8 Jan 2020	279
44	Polysarcosine-Functionalized Lipid Nanoparticles for Therapeutic mRNA Delivery Sara S. Nogueira, Anne Schlegel, Konrad Maxeiner et al. · ACS Applied Nano Materials Open access	25 Sep 2020	254
45	Personalized neoantigen vaccine NEO-PV-01 with chemotherapy and anti-PD-1 as first-line treatment for non-squamous non-small cell lung cancer Mark Magdi Awad et al. · Cancer Cell Open access	25 Aug 2022	234
46	Response definition criteria for ELISPOT assays revisited Zoe Moodie, Leah S. Price, Cécile Gouttefangeas et al. · Cancer Immunology Immunotherapy Open access	14 Jun 2010	233
47	An RNA toolbox for cancer immunotherapy Fernando Pastor, Pedro Berraondo, Iñaki Etxeberría et al. · Nature Reviews Drug Discovery Review	7 Sep 2018	230
48	Omicron BA.1 breakthrough infection drives cross-variant neutralization and memory B cell formation against conserved epitopes Jasmin Quandt, Alexander Muik, Nadine Salisch et al. · Science Immunology Open access	2 Jun 2022	229
49	Multi-Omics Characterization of the 4T1 Murine Mammary Gland Tumor Model Barbara Schrörs, Sebastian Boegel, Christian H. Albrecht et al. · Frontiers in Oncology Open access	23 Jul 2020	217
50	Local delivery of mRNA-encoded cytokines promotes antitumor immunity and tumor eradication across multiple preclinical tumor models Christian Hotz et al. · Science Translational Medicine	8 Sep 2021	216

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.